Provider review, September 2026
Healthon publishes four peptide SKUs across two compounds and two routes, three different figures for the injectable coenzyme across its own pages, and an out-of-stock notice on every one of the four.
Healthon is not a paid partner; this link may earn a commission if that changes. Full disclosure.
The catalogue lists an injectable coenzyme, a nasal spray of the same compound, an injectable growth-hormone peptide and an orally-disintegrating tablet of it. Each carries its own figure. That is a more useful catalogue than most sellers here publish, because it prices routes separately instead of quoting one number for a programme.
Every one of the four also prints, in visible text on the catalogue card, that it is out of stock. The product page for the coenzyme repeats it beside a discount banner advertising money off a six-month plan.
A price on a product that cannot be bought is still a published price, and this site records it. But a review that omitted the stock status would be describing a catalogue rather than a shop, and a reader comparing availability would be misled by the completeness of the price list.
Nothing on the site says when stock is expected, and the discount banner runs regardless.
The catalogue gives the injectable coenzyme one figure. Its own product page gives the same figure with a period attached. The site-wide navigation rail, which renders on both of those pages, gives a lower one described as a starting rate.
All three are live on the same site on the same day, and the seller reconciles none of them. This site records the catalogue figure and names the rail figure in the qualifier rather than choosing between them.
The product page compounds the problem in a smaller way. Near the price it carries a fragment reading as a first-month rate, a per-month rate afterwards, and a statement that billing occurs every three months — with the numbers those phrases belong to missing from the rendered text.
That is why the coenzyme figure is not recorded as a monthly rate here. The page states three different billing shapes near one number and settles none of them.
The growth-hormone peptide is sold both as an injection and as an orally-disintegrating tablet, at different figures, on the same catalogue. The coenzyme is sold both as an injection and as a nasal spray, again at different figures.
This is the right way round. A dissolvable tablet and a subcutaneous injection are not the same product, and a comparison that filed both under one compound at one price would be averaging two things a patient chooses between.
The roster carries all four as separate rows with the route on each, so a reader comparing injectable figures across sellers does not find a tablet among them.
Neither tablet nor spray carries a billing period on the catalogue, so all four are recorded as figures whose period the seller has not stated.
The operating company is named in the footer and again in a sentence describing itself as a patient-management platform working with independent licensed providers. Screened by that name against the regulator's warning-letter index, it returns a letter.
The letter concerns unlawful online sale of unapproved and misbranded drugs through a telehealth channel, and it is addressed to a named individual at the company. It is disclosed on the row, linked, and does not move this seller's score or position.
Beyond the letter, the standard omissions apply. No dispensing pharmacy is named. No state coverage list is published. No certificate of analysis exists anywhere on the pages read, though the site does carry third-party-testing language on its about page and its nasal-spray page.
That is the same claimed-but-unreachable shape found on several sellers in this batch, and it is recorded as a claim rather than as testing.
Healthon received an FDA warning letter issued September 2025. A warning letter discloses; it does not, on its own, disqualify a provider — see the trade-offs above for what this one concerned.
Trellis Vitality frames its program around body-composition tracking rather than scale weight, pairing NAD+, glutathione and tesamorelin with at-home biomarker panels and a 90-day re-test, and names its dispensing pharmacy, VialsRX in Houston, by address.
Read the full Trellis Vitality review
Trellis Vitality is not a paid partner; this link may earn a commission if that changes. Full disclosure.
Visit Trellis VitalityAll four peptide SKUs printed an out-of-stock notice on the catalogue when this was checked, and the product page repeated it.
Three: one on the catalogue, one on its product page, and a lower starting figure in the site-wide navigation rail. The seller reconciles none of them.
Yes. The injection, the nasal spray and the dissolvable tablet each carry their own figure, which is unusually clear for this roster.
Yes, over online sale of unapproved and misbranded drugs. It is disclosed on this seller's row and does not affect its score or position here.
No. The site claims third-party testing on two pages and publishes no certificate, PDF or index anywhere.
Healthon is not a paid partner; this link may earn a commission if that changes. Full disclosure.